The case for & against
Bull & Bear analysis
Bearish
Cibus, Inc. (NASDAQ: CBUS) is an emerging player in the agricultural biotechnology sector, focusing on precision gene editing technologies. The company specializes in developing herbicide-tolerant crops and sustainable ingredients, particularly through the commercialization of rice traits aimed at improving agricultural productivity. With a strategic emphasis on environmental sustainability and innovative solutions, Cibus is positioned to leverage advancements in gene editing to address pressing challenges in global food security and climate resilience.
Bull says
- ↑Projected >$200M annual royalties from rice traits across 5–7M acres
- ↑Sustainable ingredients royalties expected at $20–40M annually near launch
- ↑Operating expenses cut to $30M cash burn, cash runway into Q1 2027
- ↑USDA deregulation and EU progress unlock market access; seven rice deals signed
- ↑Seed‐company partnerships deepen integration, boosting customer loyalty and revenue streams
- ↑Robust fundamentals with strong growth momentum, quality, and potential short‐covering upside
Bear says
- ↓Negative earnings yield and weak profitability metrics undermine valuation
- ↓Q2 net loss of $22.1M underscores persistent operational deficits
- ↓Q2 revenue of $1M indicates very limited current commercial traction
- ↓Dependence on partner agreements risks growth if deals stall
- ↓U.S. rice trait rollout delayed until 2029 heightens adoption risk
- ↓Elevated leverage and low institutional ownership may deter investors
Earnings Call · Q2 2025 · Mgmt. Guidance
Updated 08-14-2026neutral
Transcript signals
Bull points
- Our second quarter demonstrates continued execution toward our commercial objectives, with clear progress across our focus programs in rice and partner funded and or supported sustainable ingredients, including bio fragrances that are positioning SEBAS to begin recognizing initial revenue in 2026.
- The path to revenue is really clear. Let me be even more specific about what we're building toward. Our RISE server-side tolerance traits, HT1 and HT3 alone, represent over $200 million in potential annual royalty revenue across our initial target geographies in the United States and Latin America.
- As we advance towards revenue generation, we're taking a disciplined and strategic approach to capital allocation that maximizes our near-term commercial opportunities while preserving the significant value we've created across our broader trade portfolio.
Bear points
- I want to emphasize that this process, while delayed, has not stalled and customers remain engaged and excited about the opportunity that awaits.
- It is really why, you know, gene editing is happening now and a clear path for our commercialization of many traits.
- And this is a natural evolution of how the business is evolved.
Read full transcript analysis ›